Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana.
Ghana
Korle-Bu
anti-glaucoma therapy
cost analysis
rational drug use
Journal
ClinicoEconomics and outcomes research : CEOR
ISSN: 1178-6981
Titre abrégé: Clinicoecon Outcomes Res
Pays: New Zealand
ID NLM: 101560564
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
04
2021
accepted:
28
05
2021
entrez:
9
7
2021
pubmed:
10
7
2021
medline:
10
7
2021
Statut:
epublish
Résumé
Glaucoma is the leading cause of irreversible blindness worldwide. In Ghana, 19.4% of all blindness recorded is due to glaucoma. Reducing intraocular pressure medically (using eye drops) is the evidence-based therapeutic option. To determine the rational use and undertake cost analysis of anti-glaucoma drugs among patients attending clinic at the Lions International Eye Centre (LIEC), Korle-Bu Teaching Hospital. In this cross-sectional study, we reviewed all prescriptions presented to the pharmacy unit from 01/12/2015 to 31/03/2016. The dispensed drops were classified, and all anti-glaucoma drugs were identified. This was followed by cost analysis. A total of 588 prescriptions were captured, 27.3% (161/588) contained an anti-glaucoma medication. The mean number of anti-glaucoma medications was 1.71 of which 52.7% was prescribed to females. Prostaglandin analogs (PGA) were the most prescribed (37% (102/276)), followed by beta blockers (25.4% (70/276)), carbonic anhydrase group of medicines (16.3% (45/276)), combined beta blockers (11.2% (31/276)), alpha agonists (8.7% (24/276)) and miotics (1.4% (4/276)). The median (IQR) cost of anti-glaucoma therapy per prescription per month was GHC 65.00 (GHC38.5-GHC140) about [US$16.25 (US$ 9.6-US$35)]. Azopt (Brimonidine) was the most expensive with daily treatment cost of GHC 5.8 (about US$ 1.45), whilst the least expensive drug with a daily treatment cost of GHC 0.14 (about US$ 0.035) was timolol eye drops. Prostaglandin analogs though expensive remain the most preferred treatment for managing glaucoma at the Korle-Bu Eye Centre in Ghana. This may adversely affect treatment among the poor since prostaglandins analogs are currently not covered by insurance.
Identifiants
pubmed: 34239312
doi: 10.2147/CEOR.S311058
pii: 311058
pmc: PMC8259729
doi:
Types de publication
Journal Article
Langues
eng
Pagination
619-627Informations de copyright
© 2021 Ofei-Palm et al.
Déclaration de conflit d'intérêts
The authors of this study have no conflicts of interest to declare.
Références
Indian J Pharmacol. 2013 Mar-Apr;45(2):117-20
pubmed: 23716884
BMC Health Serv Res. 2016 Jul 19;16:282
pubmed: 27430262
Can J Ophthalmol. 2009;44 Suppl 1:S7-93
pubmed: 19492005
N Engl J Med. 1998 Oct 29;339(18):1298-307
pubmed: 9791148
J Glaucoma. 2009 Feb;18(2):124-8
pubmed: 19225348
Br J Ophthalmol. 2001 Aug;85(8):897-903
pubmed: 11466240
JAMA Ophthalmol. 2013 May;131(5):651-8
pubmed: 23538512
J Glaucoma. 2002 Aug;11(4):354-8
pubmed: 12169974
Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30
pubmed: 12049575
Ophthalmology. 2009 Mar;116(3):449-54
pubmed: 19157559
ISRN Pharmacol. 2013 Dec 22;2013:768792
pubmed: 24455298
Eye (Lond). 2004 Dec;18(12):1215-24
pubmed: 15094737
Ghana Med J. 2010 Mar;44(1):25-30
pubmed: 21326988
Am J Ophthalmol. 2003 Jul;136(1):18-25
pubmed: 12834665
Patient Prefer Adherence. 2008 Feb 02;2:303-14
pubmed: 19920977
Ophthalmology. 1992 Oct;99(10):1499-504
pubmed: 1454314
Can J Ophthalmol. 2007 Feb;42(1):60-5
pubmed: 17361243
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
Ophthalmology. 1991 Mar;98(3):301-7
pubmed: 2023749
Ophthalmology. 2008 Jul;115(7):1117-1122.e1
pubmed: 18082886